MagicBullet Therapeutics
- Biotech or pharma, therapeutic R&D
The first targetable drug, Gleevec, is known as "magic bullet"that can be selectively tartet and kill disease causing cells or pathogens without harming health cells. Magic Bullet Therapeutics is pursuing of developing life-save drugs through the innovative drug discovery with global competitiveness.
MagicBullet Therapeutics is kinase based an early clinical stage biotechnology company developing new modality of novel kinome degraders, next generation kinase inhibitors with improved efficacy and selectivity and discovered novel ACK and partner protein, as a synthetic lethality, to overcome resistant mechanism harboring RAS mutants (NRAS and KRAS).
Our founders are uniquely well-positioned in developing best-in-class kinase inhibitors and extensive experience in drug discovery, clinical development and a strong mission to develop first-in-class anticancer drugs that can be conquer life-threatening diseases with unmet needs..
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}